WuXi Biologics (Cayman) Inc. has been included in the 2025 MSCI Selection Indexes for the third consecutive year. This inclusion underscores the company's sustained commitment to sustainability and its leadership in the biopharmaceutical industry, as evidenced by its high ESG ratings and recognition in areas such as product safety, corporate governance, and climate change.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.